Enveda's Experimental 'Exercise Pill' ENV-308 Shows Promise in First Human Trial, May Reduce Appetite and Mimic Physical Activity
Biotech company Enveda has announced encouraging results from the first clinical trial of its experimental drug, ENV-308, designed to curb appetite and replicate some of the body's effects of physical activity. The pill aims to harness the benefits of lactate phenylalanine (Lac-Phe), a molecule naturally produced by the body during vigorous exercise, which signals the brain to reduce the urge to eat. Scientists at Stanford discovered Lac-Phe in 2022. The Phase I clinical trial involved 88 healthy adults and primarily focused on assessing the drug's safety and tolerability. Participants tolerated ENV-308 across all tested doses, with the company reporting an "exceptional gastrointestinal safety profile." Early results also indicate that ENV-308 lowers leptin levels in both animals and humans, particularly in individuals with high initial levels of the hormone, which regulates hunger. This reduction in leptin suggests a potential role in weight management by decreasing hunger. Additionally, preclinical model... 
